Advice
following a full submission:
vildagliptin (Galvus®) is accepted for restricted use within NHS Scotland.
Indication under review: Treatment of type 2 diabetes mellitus in adults as triple oral therapy in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.
SMC restriction: as an alternative dipeptidyl peptidase-4 inhibitor option.
Treatment with vildagliptin reduces HbA1c levels significantly more than placebo when used in combination with metformin and a sulphonylurea. A Bayesian network meta-analysis suggested similar efficacy to another dipeptidyl peptidase-4 inhibitor.
Download detailed advice197KB (PDF)
Medicine details
- Medicine name:
- vildagliptin (Galvus)
- SMC ID:
- 875/13
- Indication:
- Treatment of type 2 diabetes mellitus in adults as triple oral therapy in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 December 2013